Get the Stockscreener App
9.80
3.27%
0.31
After Hours:
10.00
0.20
+2.04%
Cervomed Inc stock is traded at $9.80, with a volume of 336.69K.
It is up +3.27% in the last 24 hours and up +8.29% over the past month.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$9.49
Open:
$9.77
24h Volume:
336.69K
Relative Volume:
0.08
Market Cap:
$84.24M
Revenue:
-
Net Income/Loss:
$-6.42M
P/E Ratio:
-1.7496
EPS:
-5.6013
Net Cash Flow:
$-7.45M
1W Performance:
+15.70%
1M Performance:
+8.29%
6M Performance:
-30.25%
1Y Performance:
-60.80%
1-Day Range:
$9.60
$10.40
1-Week Range:
$7.88
$10.89
52-Week Range:
$1.80
$25.69
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
9.80 | 84.24M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
What Will CervoMed Inc (NASDAQ: CRVO) Be Like In 2025 - Stocksregister
CervoMed Inc. Announces Executive Appointments and Officer Departure By Investing.com - Investing.com South Africa
CervoMed Announces Executive Appointments and Changes - MSN
CervoMed Inc. Announces Executive Appointments and Officer Departure - Investing.com Australia
CervoMed (CRVO) to Present Key Findings on Dementia Drug at Inte - GuruFocus
CervoMed (CRVO) Reports Positive Phase 2b Results for Neflamapim - GuruFocus
CervoMed Reports Positive Phase 2b Trial Results - TipRanks
Brokerages Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $27.50 - Defense World
CervoMed To Present Phase 2b Data On Neflamapimod's Impact On DLB At AD/PD 2025 - Nasdaq
CervoMed to present results on Phase 2b RewinD-LB study - TipRanks
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025 - GlobeNewswire
CervoMed Inc. to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD 2025 - MarketScreener
Virtu Financial LLC Invests $26,000 in CervoMed Inc. (NASDAQ:CRVO) - Defense World
Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha
CervoMed (CRVO) Projected to Post Quarterly Earnings on Friday - Defense World
FY2025 EPS Estimates for CervoMed Lowered by Chardan Capital - Defense World
CervoMed (NASDAQ:CRVO) Given Buy Rating at D. Boral Capital - Defense World
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
CervoMed Announces Oral Presentation at 19th International - GlobeNewswire
CervoMed Inc. to Present Findings on Neflamapimod in Dementia with Lewy Bodies at AP/PD™ Conference 2025 - Nasdaq
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™) - The Manila Times
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™) - TradingView
New Clinical Data: CervoMed's Breakthrough Dementia Drug Results Revealed at Global Conference - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats - Seeking Alpha
CervoMed Stock: Extension Study Data In Dementia Is Potentially Exciting, With Caveats - Seeking Alpha
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Roth Capital Issues Negative Forecast for CervoMed Earnings - Defense World
Brokers Offer Predictions for CervoMed Q1 Earnings - Defense World
Q1 Earnings Forecast for CervoMed Issued By Roth Capital - Defense World
Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts? - Insider Monkey
CervoMed reports FY24 EPS ($2.02), consensus ($1.85) - MSN
CervoMed Inc (CRVO) Reports Q4 Net Loss of $16.3 Million, Grant Revenue at $9.7 Million - GuruFocus.com
Roth Mkm Issues Positive Forecast for CervoMed (NASDAQ:CRVO) Stock Price - Defense World
CervoMed (NASDAQ:CRVO) Given New $21.00 Price Target at Canaccord Genuity Group - Defense World
Best Biotech Stocks To Watch Now – March 17th - Defense World
10 Best Short Squeeze Stocks To Buy According to Analysts - Insider Monkey
CervoMed price target raised to $20 from $15 at Roth MKM - TipRanks
Following A Monumental March, Can CRVO Keep The Rally Going In April? - RTTNews
CervoMed sees cash runway into mid-2026 - MSN
CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
CervoMed price target raised to $21 from $12 at Canaccord - TipRanks
CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now - Insider Monkey
Cervomed Inc. Faces Financial Hurdles Due to Regulatory Restrictions on Public Float - TipRanks
Small Cap Stocks To Watch NowMarch 13th - MarketBeat
Peering Into CervoMed's Recent Short Interest - Benzinga
CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
CervoMed's Breakthrough in Lewy Body Dementia Treatment Shows Promise in Latest Financial Report - StockTitan
Why CervoMed Inc. (CRVO) Soared Last Week? - Insider Monkey
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):